Search research articles
Contact Us
Filters
Showing results (371-380 of 578) with videos related to
Page
of 58
Sort By:
Future Oncology (London, England)
|
March 19, 2024
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Gynecologic Oncology
|
March 15, 2024
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer
Paul Gass, Falk C Thiel, Lothar Häberle, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Gynecologic Oncology
|
September 15, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 21, 2021
Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al
Dirk Timmerman, David Cibula, François Planchamp, et al.
JAMA Oncology
|
September 11, 2015
Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing
Frédéric Amant, Magali Verheecke, Iwona Wlodarska, et al.
BMC Medicine
|
June 24, 2017
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
Tushar Tomar, Nicolette G Alkema, Leroy Schreuder, et al.
Journal of Cancer Research and Clinical Oncology
|
February 28, 2019
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
Jun Guan, Silvia Darb-Esfahani, Rolf Richter, et al.
Frontiers in Oncology
|
July 12, 2024
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance
Yani Berckmans, Hila M Ene, Kerem Ben-Meir, et al.
Carcinogenesis
|
December 15, 2010
Progesterone receptor gene variants and risk of endometrial cancer
Tracy A O'Mara, Paul Fahey, Kaltin Ferguson, et al.
Page
of 58
Search research articles
Search
Showing results (371-380 of 578) with videos related to
Sort By:
Page
of 58
Future Oncology (London, England)
|
March 19, 2024
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Gynecologic Oncology
|
March 15, 2024
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer
Paul Gass, Falk C Thiel, Lothar Häberle, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Gynecologic Oncology
|
September 15, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 21, 2021
Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al
Dirk Timmerman, David Cibula, François Planchamp, et al.
JAMA Oncology
|
September 11, 2015
Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing
Frédéric Amant, Magali Verheecke, Iwona Wlodarska, et al.
BMC Medicine
|
June 24, 2017
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
Tushar Tomar, Nicolette G Alkema, Leroy Schreuder, et al.
Journal of Cancer Research and Clinical Oncology
|
February 28, 2019
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
Jun Guan, Silvia Darb-Esfahani, Rolf Richter, et al.
Frontiers in Oncology
|
July 12, 2024
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance
Yani Berckmans, Hila M Ene, Kerem Ben-Meir, et al.
Carcinogenesis
|
December 15, 2010
Progesterone receptor gene variants and risk of endometrial cancer
Tracy A O'Mara, Paul Fahey, Kaltin Ferguson, et al.
Page
of 58